Compare BOX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | ACAD |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 2014 | 2000 |
| Metric | BOX | ACAD |
|---|---|---|
| Price | $28.66 | $26.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $35.57 | $30.55 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.08 | 0.02 |
| Revenue | $506,142,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $9.41 | $18.80 |
| Revenue Next Year | $8.15 | $11.70 |
| P/E Ratio | ★ $359.63 | $1,320.00 |
| Revenue Growth | 26.98 | ★ 40.45 |
| 52 Week Low | $21.34 | $19.69 |
| 52 Week High | $33.88 | $28.35 |
| Indicator | BOX | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 74.40 |
| Support Level | $23.52 | $25.40 |
| Resistance Level | $28.80 | $27.79 |
| Average True Range (ATR) | 0.95 | 0.94 |
| MACD | 0.29 | 0.23 |
| Stochastic Oscillator | 89.21 | 82.17 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.